Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles
about
Systems virology identifies a mitochondrial fatty acid oxidation enzyme, dodecenoyl coenzyme A delta isomerase, required for hepatitis C virus replication and likely pathogenesisEntry inhibitors: New advances in HCV treatmentNew hepatitis C virus drug discovery strategies and model systemsImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationMouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell LineIdentification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2Structural and genetic basis for development of broadly neutralizing influenza antibodiesThe Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic VirusesMechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidolAnalysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolutionFusogenic properties of the ectodomains of hepatitis C virus envelope proteins.The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transportersRegulated Entry of Hepatitis C Virus into Hepatocytes.Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycleLipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entryThe rate of hepatitis C virus infection initiation in vitro is directly related to particle density.Hepatitis C virus experimental model systems and antiviral drug research.MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles.Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.Potential treatment options and future research to increase hepatitis C virus treatment response ratePhenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entryHepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.How hepatitis C virus invades hepatocytes: the mystery of viral entryKnow your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation.Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection.Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a trans-Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in both HCV Entry and Morphogenesis.Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins.Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions.The Antiviral Drug Arbidol Inhibits Zika Virus.Hepatitis C virus entry into the hepatocyteHCV Receptors and Virus Entry
P2860
Q24631218-028C88F2-C425-4550-AC8C-A6B0302DBB9AQ26770817-072B2E37-607E-4021-8B50-7A2BD45BC5CFQ26851159-B82FBF58-6AE1-405B-A5AE-CDDAE5963BA1Q26864485-54C6650F-46E5-4B9A-9D24-9B110DC79312Q27490526-E68D97C0-50C8-4661-961D-9BA21F4F31B4Q27666330-2CC42E3C-5CB5-4F03-959C-79AF7EB837BAQ27682070-A0F5CFDE-5C77-434D-A066-B19FB9706E54Q28271798-626E882C-980A-4550-BDB0-AA781717F4D4Q28476811-559CD62B-DC80-4025-A272-AEA428760BA9Q28659586-7D8297EC-A61C-4106-9FDE-4D20620B11BDQ30360986-821F988D-5784-436F-A90F-BB6456C39789Q30440948-1D14EE2A-50FC-4A35-B72F-7A536F56ACFBQ33753913-850163E7-DE9B-4553-B5D2-156B781D1F81Q33877342-3722D4A2-F753-407A-B185-59E332E1FE38Q33893794-E5B8233A-ABD3-484C-A361-DB84C26C3719Q34062532-F2608190-480B-451D-9E5C-A9508D8A35E4Q34158687-E3BFCACF-5199-4302-933B-1876C8B3D9E2Q34235286-614AB154-58C7-469D-972C-DEDFAF1A8A34Q34387277-E0AC7FFF-900C-4DFB-98AB-05DCAA16B925Q34540988-8411F428-979E-4F05-86F3-A1FF7045F925Q34576190-DD206507-3EBA-48AA-8F07-932BA2E24008Q34636137-80EA052D-BA7C-46A1-AEBA-2B85E251A6F7Q34652154-0248EBB1-90B0-484C-81E3-1D1848FD7F08Q36559862-5A2431DA-A431-451D-BB81-2D825617DC5DQ37015738-7138D667-C90D-4397-BFB7-285DFB579E89Q37609487-D5AB760D-AAC4-4904-95D2-E8840DD907B1Q37682499-AB5E99D3-9FBD-43A5-9F7E-CF1D14F4DC4DQ37688134-8DADF26D-63DF-4823-A17C-54FA417E664EQ37864742-E64C9DD7-5054-438C-8AC8-7BACF7B53294Q38166372-427A8493-4E0E-4D34-A209-B86173DFE2ABQ38720669-1A849FED-250B-4078-8CFA-72A9D72DAB4BQ39068693-A7A04EC7-9E2D-4B79-8F2D-B5170B3BCF13Q39318833-C70BE8F0-4757-4587-89B4-E8337D775666Q39532092-76E8F9A3-B260-420B-B21B-F3344BFC2A71Q39552847-B6684CCE-F6D7-4B90-8D43-0C6A78264CB9Q39692571-20A5366D-4C54-4347-99EC-A5DA920CA25DQ40141933-B2851D8B-A1D7-4DA4-A4D5-44A776888F6DQ55084371-B1E71A6A-0425-4884-BC26-92258F2FDC86Q56911131-7DE517ED-4B5D-4B9C-9AB9-0A64EEBA40FBQ57564402-E2889FC9-FE07-44F0-B152-92DFF81F7A2C
P2860
Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@ast
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@en
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@nl
type
label
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@ast
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@en
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@nl
prefLabel
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@ast
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@en
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@nl
P2093
P2860
P356
P1476
Low pH-dependent Hepatitis C V ...... and Density of Virus Particles
@en
P2093
Eve-Isabelle Pécheur
Sibylle Haid
Thomas Pietschmann
P2860
P304
P356
10.1074/JBC.M109.014647
P407
P577
2009-06-26T00:00:00Z